Answers are grounded in this paper and cite their sources.
Background UK guidelines recommend a faecal immunochemical test for haemoglobin (FIT) cut-off ≥10 µg haemoglobin/gram faeces (µg/g) to triage symptomatic adults in primary care for urgent colorectal cancer (CRC) investigation. There is a paucity of evidence examining diagnostic accuracy of FIT in younger adults, in whom CRC incidence is rising. Objective To assess performance of FIT in symptomatic patients <50 years compared with ≥50 years. Design Medline and Embase were searched on 22 September 2025 for studies reporting use of FIT in symptomatic patients <50 years tested in primary care. Data were extracted to calculate performance characteristics for CRC by age group (<50, ≥50 years). Results Of 4950 records identified, 12 studies were included reporting the performance of FIT in 69 092 symptomatic patients <50 years. The overall pooled prevalence of CRC in symptomatic cohorts using the cut-off FIT ≥10 µg/g was 0.35% (95% CI 0.28% to 0.44%, I2=39.4%) in patients <50 and prevalence ranged from 0.91% to 2.54% in those ≥50 years. Sensitivity ranged from 50% to 100.0% and specificity from 82.8% to 94.2% in patients <50 compared with ≥50 years: 85.1%–93.0% and 73.6%–90.7%, respectively. In patients <50 vs ≥50 years, positive predictive value (PPV) was lower (1.4%–8.6% vs 6.2%–10.4%) and number needed to scope (NNS) was higher (12–73 vs 10–16). PPV and NNS improved at higher cut-offs (≥100, ≥150 µg/g) in patients <50 with a modest trade-off in sensitivity, becoming comparable to performance in those ≥50 years at FIT ≥10 µg/g. Conclusions Overall prevalence of CRC in symptomatic patients <50 years undergoing FIT is low. Further work assessing tailored FIT thresholds or risk prediction in younger symptomatic populations is needed. PROSPERO registration number CRD42025638390.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: